AlShanableh Zain, Woodall Anna, Chisdak Michelle, Yabes Jonathan G, Sterns Richard H, Weisbord Steven D, Rondon-Berrios Helbert
Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Kidney360. 2025 Sep 1;6(9):1462-1471. doi: 10.34067/KID.0000000830. Epub 2025 Apr 24.
Proactive desmopressin was associated with reduced overcorrection of hyponatremia compared with reactive/rescue desmopressin or no desmopressin. No significant differences in adverse events were observed between proactive, reactive/rescue, and no desmopressin strategies. Plasma sodium was checked more often in the proactive desmopressin group.
Coadministration of hypertonic saline (HTS) 3% and desmopressin from the outset of treatment (“DDAVP clamp” or proactive desmopressin) has been suggested to prevent inadvertent overcorrection of hyponatremia, but its effectiveness and safety remain uncertain.
We identified adult patients hospitalized between July 1, 2018, and June 30, 2023, at four University of Pittsburgh Medical Center hospitals with a plasma sodium (PNa) ≤120 mEq/L at admission or during hospitalization who were treated with HTS. We compared outcomes between patients who were treated with proactive desmopressin and those who either did not receive desmopressin or received it using a reactive/rescue strategy.
A total of 184 patient admissions (57.6% female, mean age 60.6 years) met inclusion and exclusion criteria. Hyponatremia was chronic in 93.5% of patients; leading causes were syndrome of inappropriate antidiuresis (51.6%), hypovolemia (25.5%), and low solute intake (15.8%), and 20.1% had seizures. Cases treated with proactive desmopressin (=44) were compared with cases treated without proactive desmopressin (=140). Despite a lower baseline PNa (110.2±6.3 versus 115.2±7.2 mEq/L, < 0.001), correction by >8 mEq/L (6.8% versus 27.1%, = 0.009) or >10 mEq/L (0% versus 15%, = 0.014) within the first 24 hours was significantly less frequent in the proactive desmopressin group. Hospital mortality (6.8% versus 6.4%, > 0.99), length of hospital (12.5 versus 11.7 days, = 0.624) and intensive care unit stays (6 versus 5.5 days, = 0.578), fluid overload (9.1% versus 9.5%, > 0.99), and worsening of hyponatremia (2.3% versus 1.5%, > 0.99) were similar in the two groups, but PNa was checked significantly more often in the proactive desmopressin group (20.9 versus 17.4, < 0.001). No cases of osmotic demyelination syndrome and no deaths from cerebral edema were identified.
Treating severe hyponatremia with HTS and proactive desmopressin was associated with lower rates of overcorrection without significant adverse events compared with HTS without proactive desmopressin.
与反应性/挽救性使用去氨加压素或不使用去氨加压素相比,预防性使用去氨加压素与低钠血症过度纠正的减少相关。在预防性、反应性/挽救性和不使用去氨加压素策略之间,未观察到不良事件有显著差异。预防性使用去氨加压素组更频繁地检查血钠。
有人建议从治疗开始就联合使用3%高渗盐水(HTS)和去氨加压素(“去氨加压素钳夹”或预防性去氨加压素)以防止低钠血症的意外过度纠正,但其有效性和安全性仍不确定。
我们确定了2018年7月1日至2023年6月30日期间在匹兹堡大学医学中心的四家医院住院的成年患者,这些患者入院时或住院期间血钠(PNa)≤120 mEq/L且接受了HTS治疗。我们比较了接受预防性去氨加压素治疗的患者与未接受去氨加压素治疗或采用反应性/挽救性策略接受去氨加压素治疗的患者的结局。
共有184例患者入院(57.6%为女性,平均年龄60.6岁)符合纳入和排除标准。93.5%的患者低钠血症为慢性;主要病因是抗利尿激素分泌失调综合征(51.6%)、血容量不足(25.5%)和溶质摄入低(15.8%),20.1%的患者有癫痫发作。将接受预防性去氨加压素治疗的病例(n = 44)与未接受预防性去氨加压素治疗的病例(n = 140)进行比较。尽管基线PNa较低(110.2±6.3对115.2±7.2 mEq/L,P < 0.001),但预防性去氨加压素组在最初24小时内血钠纠正>8 mEq/L(6.8%对27.1%,P = 0.009)或>10 mEq/L(0%对15%,P = 0.014)的频率显著较低。两组的医院死亡率(6.8%对6.4%,P > 0.99)、住院时间(12.5对11.7天,P = 0.624)和重症监护病房住院时间(6对5.5天,P = 0.578)、液体超负荷(9.1%对9.5%,P > 0.99)以及低钠血症恶化(2.3%对1.5%,P > 0.99)相似,但预防性去氨加压素组检查PNa的频率显著更高(20.9次对17.4次,P < 0.001)。未发现渗透性脱髓鞘综合征病例,也没有因脑水肿死亡的病例。
与不使用预防性去氨加压素的HTS相比,使用HTS和预防性去氨加压素治疗严重低钠血症与过度纠正率较低相关,且无显著不良事件。